Overview

A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine

Status:
Not yet recruiting

Trial end date:
2023-01-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Leucovorin
Methotrexate
Sulfasalazine